AUS
NZ
UK
CA
USA
IND
Highlights
- Immunotherapy and addiction treatment trials gather momentum
- Diagnostic innovations advance in Alzheimer's research
- Drilling activity reinforces resource expansion in West Africa
In a landscape often dominated by the blue-chip names of the FTSE 100, small-cap companies continue to carve out a compelling presence with research breakthroughs, trial progress, and resource discoveries. The recent updates from Scancell, IXICO, Solvonis Therapeutics, hVIVO, Thor Explorations, and Oriole Resources reflect the dynamic potential found outside the major indices.
Scancell Holdings (LSE:SCLP) has advanced its melanoma immunotherapy platform, iSCIB1+, showing encouraging results in Phase II clinical studies. The therapy, targeting an unmet need in skin cancer care, is being assessed aLSEgside standard treatments, bringing attention to next-generation immunological approaches in oncology.
IXICO (LSE:IXI) continues to expand its capabilities in neurological diagnostics. Through a strategic partnership with a global Alzheimer’s platform, the company is enhancing access to critical biomarker data. This effort strengthens its position in the evolving field of blood-based testing and vascular imaging – both crucial in the early and accurate identification of Alzheimer’s-related conditions.
Solvonis Therapeutics (LSE:SVNS) has launched key regulatory steps in the United States for SVN‑002, a sublingual esketamine-based treatment for alcohol use disorder. Utilizing existing clinical data as a foundation, the company aims to streamline its FDA submission process, moving closer to offering new options for addiction therapy.
hVIVO (LSE:HVO), known for its human challenge studies, reaffirmed its revenue targets while signaling robust commercial interest. A strong sales pipeline includes upcoming contracts that could surpass previous records, emphasizing continued demand for its niche services in clinical testing and infectious disease trials.
Thor Explorations (LSE:THX) has delivered promising initial drilling data from its Guitry gold project in Côte d'Ivoire. With mineralisation confirmed at surface and depth, the activity strengthens the company's portfolio and highlights the exploration upside within West Africa's mineral-rich terrains.
Oriole Resources (LSE:ORR) reported extended mineralisation at its Mbe gold project in Cameroon. The expansion, now reaching a new structural depth, is supported by over 250 gold intersections. The company anticipates releasing its maiden resource estimate in late 2025, offering fresh insights into one of its core assets.
Together, these developments illustrate how small-cap players are steadily building momentum through focused research, international partnerships, and resource exploration. While they may operate outside the FTSE100 spotlight, their strategies reflect significant activity across health sciences and natural resources, contributing to the broader market landscape.
